Dashboard
Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.92 times
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.92 times
Poor long term growth as Operating profit has grown by an annual rate -7.56% of over the last 5 years
Stock is technically in a Bearish range
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
INR 1,067 Cr (Micro Cap)
19.00
40
0.47%
0.37
10.89%
2.01
Total Returns (Price + Dividend) 
Latest dividend: 1.5 per share ex-dividend date: Sep-11-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Bajaj Healthcare Ltd is Rated Sell
Bajaj Healthcare Ltd is rated Sell by MarketsMOJO. This rating was last updated on 21 July 2026, reflecting a shift from a previous Hold stance. However, the analysis and financial metrics presented here are based on the stock’s current position as of 21 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Bajaj Healthcare Ltd Faces Bearish Momentum Amid Technical Downgrade
Bajaj Healthcare Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. The company’s recent downgrade from a Hold to a Sell rating by MarketsMojo, coupled with deteriorating technical parameters, underscores growing investor caution amid underperformance relative to broader market benchmarks.
Read More
Bajaj Healthcare Ltd is Rated Sell by MarketsMOJO
Bajaj Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 10 November 2026, providing investors with an up-to-date view of the company’s performance and outlook.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
18-Nov-2026 | Source : BSEIntimation for allotment of 26710 Equity Shares pursuant to exercise of ESOPs
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
27-Oct-2026 | Source : BSETranscript of Earnings Call for Q2H1FY27
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
19-Oct-2026 | Source : BSEIntimation for Audio Recording of Earnings Call for Q2FY27
Corporate Actions 
No Upcoming Board Meetings
Bajaj Healthcare Ltd has declared 30% dividend, ex-date: 11 Sep 26
Bajaj Healthcare Ltd has announced 5:10 stock split, ex-date: 28 Sep 21
Bajaj Healthcare Ltd has announced 1:1 bonus issue, ex-date: 09 Apr 19
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 3 Schemes (1.69%)
Held by 15 FIIs (2.09%)
Sajankumar Rameshwarlal Bajaj (36.61%)
Deepak Ramanlal Joshi (2.32%)
30.81%
Quarterly Results Snapshot (Standalone) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 18.92% vs 11.14% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 26.82% vs 17.44% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 11.84% vs 14.89% in Sep 2024
Growth in half year ended Sep 2025 is 38.19% vs 132.13% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 17.99% vs 14.32% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 36.33% vs 152.57% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 12.61% vs 14.61% in Mar 2025
YoY Growth in year ended Mar 2026 is -60.08% vs 147.14% in Mar 2025